List of Anjeso drug patents

Anjeso is owned by Baudax.

Anjeso contains Meloxicam.

Anjeso has a total of 8 drug patents out of which 1 drug patent has expired.

Expired drug patents of Anjeso are:

  • US8512727

Anjeso was authorised for market use on 20 February, 2020.

Anjeso is available in solution;intravenous dosage forms.

Anjeso can be used as management of moderate-to-severe pain by intravenous injection, management of moderate-to-severe pain by intravenous injection in patients with mild renal impairment, management of moderate-to-severe pain by injection.

The generics of Anjeso are possible to be released after 08 March, 2039.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8512727 BAUDAX Nanoparticulate meloxicam formulations
Dec, 2022

(3 months ago)

US10463673 BAUDAX Nanoparticulate meloxicam formulations
Feb, 2024

(10 months from now)

US10471067 BAUDAX Nanoparticulate meloxicam formulations
Feb, 2024

(10 months from now)

US9974746 BAUDAX Reduction of flake-like aggregation in nanoparticulate active agent compositions
May, 2030

(7 years from now)

US10709713 BAUDAX Nanoparticulate meloxicam formulations
May, 2030

(7 years from now)

US11253478 BAUDAX Reduction of flake-like aggregation in nanoparticulate active agent compositions
May, 2030

(7 years from now)

US11458145 BAUDAX Methods of administering intravenous meloxicam in a bolus dose
Mar, 2039

(15 years from now)

US10881663 BAUDAX Method of treating pain in elderly patients with mild renal impairment
Mar, 2039

(15 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Feb 20, 2023

Drugs and Companies using MELOXICAM ingredient

Market Authorisation Date: 20 February, 2020

Treatment: Management of moderate-to-severe pain by intravenous injection; Management of moderate-to-severe pain by injection; Management of moderate-to-severe pain by intravenous injection in patients with mild...

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

ANJESO family patents

28

United States

10

Japan

8

European Union

3

Canada

3

Spain

3

Australia

2

Hungary

2

Denmark

2

Korea, Republic of

2

China

1

Germany

1

Austria

1

Taiwan, Province of China

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic